Board of Directors

Aboard of renowned experts and managers with international experience in a large spectrum of complementary fields assists the company.

Christian Bloy, CEO and Co-founder

Christian has more than 35 years of experience in R&D, Manufacturing and Regulatory affairs. Before founding Clevexel Pharma, Christian was site manager and senior director of drug development for Europe at Cephalon Inc.. Prior to Cephalon, he was Senior Director of R&D in Immune Mediated Diseases and Transplant at Genzyme. He was previously on the Board of Directors of Cassenne Laboratory (Hoechst Marion Roussel group), Flamel Technology, and Genzyme Polyclonals. Christian is the author of more than 35 peer-reviewed articles and 6 patents, including one on the Central Nervous System. He holds a Ph.D. in Immuno-hematology from the Paris VI University.

Antoine Bejui, Board member

Antoine has started his career in M&A before joining Ernst & Young (Transaction Advisory Services). Antoine became later CFO of a luxury company. He graduated from ESCP-EAP.

Stéphane Dreyer, Board member

Stéphane began his career by founding an import-export company in South America. Then he was in charge of several real estate development projects in this region. He subsequently moved to the Middle East where he still resides. He was Sales Director then Administrative and Financial Director of an industrial group. At the same time, Stéphane also founded a Consulting and Management company. Finally Stéphane participated in several fundraising in the Medcare industry and also waste treatment. Stéphane is a graduate from ISG, the International Management University of Asia (Tokyo – Japan) and the Manhattan Institute of Management (NY – USA)

Marc Le Bozec, Board member

Bord Member at Clevexel Pharma, Marc is also Fund manager at Arbevel and CEO of CYTOO (France). From 2006 until 2013 Marc was the CFO of Cellectis, where he raised ca. €120m on capital markets. Prior to this he started his own Business BioProtein Technologies and headed it after several years of organizational consulting at Bossard Consultants and strategy consulting at Arthur D. Little. Marc is graduated from HEC School of Management.

Stanislas-Léonard Malmezat, Board member

Stanislas is Financial Director at Domain Therapeutics. He started his career as product manager junior at Johnson & Johnson (Paris office). He worked as Junior Associate in a French Venture Capital fund specialized in Biotechnology. He spent two years as senior consultant in the Corporate Restructuring & Transaction Services department of Ernst & Young and three years as Senior Associate at Duff & Phelps Paris working primarily with the Merger and Acquisition team. In 2011, Stanislas joined Rarecells Diagnostics to be in charge of corporate affairs and assist the founder in fund raising and business development before before joining CleveXel Pharma when he was Financial Director for 4 years.